JP2013523708A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523708A5 JP2013523708A5 JP2013501945A JP2013501945A JP2013523708A5 JP 2013523708 A5 JP2013523708 A5 JP 2013523708A5 JP 2013501945 A JP2013501945 A JP 2013501945A JP 2013501945 A JP2013501945 A JP 2013501945A JP 2013523708 A5 JP2013523708 A5 JP 2013523708A5
- Authority
- JP
- Japan
- Prior art keywords
- cbdv
- therapeutically effective
- phytocannabinoid
- effective amount
- thcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims 28
- 241001471082 Colocasia bobone disease-associated cytorhabdovirus Species 0.000 claims 28
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 claims 28
- 241000218236 Cannabis Species 0.000 claims 13
- 239000000419 plant extract Substances 0.000 claims 13
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 claims 12
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 claims 12
- 241001483078 Phyto Species 0.000 claims 6
- 239000001961 anticonvulsive agent Substances 0.000 claims 6
- 229930003827 cannabinoid Natural products 0.000 claims 6
- 239000003557 cannabinoid Substances 0.000 claims 6
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims 5
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims 5
- 229950011318 cannabidiol Drugs 0.000 claims 5
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims 5
- 206010010904 Convulsion Diseases 0.000 claims 4
- 230000001773 anti-convulsant effect Effects 0.000 claims 3
- 229960003965 antiepileptics Drugs 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 108090000312 Calcium Channels Proteins 0.000 claims 2
- 102000003922 Calcium Channels Human genes 0.000 claims 2
- 108010052164 Sodium Channels Proteins 0.000 claims 2
- 102000018674 Sodium Channels Human genes 0.000 claims 2
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims 2
- 230000010534 mechanism of action Effects 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 230000036982 action potential Effects 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229940088679 drug related substance Drugs 0.000 claims 1
- 238000010304 firing Methods 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 229930003658 monoterpene Natural products 0.000 claims 1
- 150000002773 monoterpene derivatives Chemical class 0.000 claims 1
- 235000002577 monoterpenes Nutrition 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 claims 1
- 229940033329 phytosphingosine Drugs 0.000 claims 1
- 229930004725 sesquiterpene Natural products 0.000 claims 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 210000003478 temporal lobe Anatomy 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1005364.3A GB2479153B (en) | 2010-03-30 | 2010-03-30 | The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy |
| GB1005364.3 | 2010-03-30 | ||
| GB1100042.9A GB2487183B (en) | 2011-01-04 | 2011-01-04 | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
| GB1100042.9 | 2011-01-04 | ||
| PCT/GB2011/050649 WO2011121351A1 (en) | 2010-03-30 | 2011-03-30 | Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523708A JP2013523708A (ja) | 2013-06-17 |
| JP2013523708A5 true JP2013523708A5 (https=) | 2014-05-08 |
| JP5918748B2 JP5918748B2 (ja) | 2016-05-18 |
Family
ID=43983229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501945A Active JP5918748B2 (ja) | 2010-03-30 | 2011-03-30 | てんかんの治療におけるフィトカンナビノイドカンナビジバリン（ｃｂｄｖ）の使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9125859B2 (https=) |
| EP (2) | EP3763361B1 (https=) |
| JP (1) | JP5918748B2 (https=) |
| KR (1) | KR101849703B1 (https=) |
| CN (1) | CN103025325B (https=) |
| AR (1) | AR080730A1 (https=) |
| AU (3) | AU2011234225B2 (https=) |
| BR (1) | BR112012024480A8 (https=) |
| CA (1) | CA2794620C (https=) |
| EA (1) | EA036044B1 (https=) |
| IL (1) | IL222132B (https=) |
| MX (1) | MX2012011033A (https=) |
| MY (1) | MY162129A (https=) |
| NZ (1) | NZ602925A (https=) |
| PH (1) | PH12012501902A1 (https=) |
| SG (2) | SG184236A1 (https=) |
| TW (1) | TWI583374B (https=) |
| WO (1) | WO2011121351A1 (https=) |
| ZA (1) | ZA201208141B (https=) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9168278B2 (en) * | 2004-11-16 | 2015-10-27 | Gw Pharma Limited | Use for cannabinoid |
| GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| GB2487183B (en) * | 2011-01-04 | 2018-10-03 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US10774288B2 (en) | 2013-09-18 | 2020-09-15 | The Werc Shop, LLC | Terpene-based compositions, processes, methodologies for creation and products thereby |
| LT3062606T (lt) * | 2013-10-29 | 2019-07-10 | Biotech Institute, Llc | Specializuotų kanapių selekcija, gamyba, perdirbimas ir panaudojimas |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) * | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| CA2961410C (en) | 2014-09-16 | 2023-07-11 | India Globalization Capital, Inc. | Cannabinoid composition and method for treating pain |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| CA2974895A1 (en) | 2015-01-25 | 2016-07-28 | India Globalization Capital, Inc. | Composition and method for treating seizure disorders |
| US10238745B2 (en) | 2015-01-31 | 2019-03-26 | Constance Therapeutics, Inc. | Cannabinoid composition and products including α-tocopherol |
| IL253664B (en) | 2015-01-31 | 2022-09-01 | Constance Therapeutics Inc | Production method for extracting oil from cannabis and preparations |
| BR112017018316A2 (pt) | 2015-02-27 | 2018-04-17 | Ebbu Llc | composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral |
| US20160317468A1 (en) * | 2015-04-28 | 2016-11-03 | Raman Sankar | Uses of cannabidiol for treatment of infantile spasms |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) * | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| US10596159B2 (en) | 2015-08-12 | 2020-03-24 | India Globalization Capital, Inc. | Method and composition for treating cachexia and eating disorders |
| CA3006182A1 (en) | 2015-11-24 | 2017-06-01 | Constance Therapeutics, Inc. | Cannabis oil compositions and methods for preparation thereof |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| GB2549278B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Use of cannabidivarin in the treatment of autism spectrum disorder |
| US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
| US10053407B2 (en) | 2016-06-01 | 2018-08-21 | S&B Pharma, Inc. | Crystalline cannabidivarin |
| US10399920B2 (en) | 2016-06-01 | 2019-09-03 | S&B Pharma, Inc. | Crystalline form of cannabidiol |
| EP3471746A4 (en) | 2016-06-15 | 2020-02-26 | India Globalization Capital, Inc. | METHOD AND COMPOSITION FOR TREATING CRAMPING SEASONS |
| WO2018000094A1 (en) | 2016-06-29 | 2018-01-04 | CannScience Innovations Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| CA3031810A1 (en) | 2016-08-03 | 2018-02-08 | Zelda Therapeutics Operations Pty Ltd | Cannabis composition |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| WO2018044953A1 (en) | 2016-08-29 | 2018-03-08 | Ebbu, LLC | Water soluble compositions comprising purified cannabinoids |
| US12485129B2 (en) | 2016-08-29 | 2025-12-02 | Canopy Growth Corporation | Water soluble compositions comprising purified cannabinoids |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| CN108236608B (zh) * | 2016-12-27 | 2020-05-08 | 汉义生物科技（北京）有限公司 | 大麻二酚与氨己烯酸的药物组合物及其用途 |
| CN108245517B (zh) * | 2016-12-29 | 2020-05-08 | 汉义生物科技（北京）有限公司 | 大麻二酚与拉莫三嗪的药物组合物及其用途 |
| CN108245510B (zh) * | 2016-12-29 | 2020-11-20 | 汉义生物科技（北京）有限公司 | 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途 |
| CN108245499B (zh) * | 2016-12-29 | 2020-11-20 | 汉义生物科技（北京）有限公司 | 大麻二酚与双链脂肪酸类抗癫痫药物的组合物及其用途 |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| CN110582206A (zh) * | 2017-03-01 | 2019-12-17 | 凯诺比生长公司 | 包含纯化的大麻素和/或纯化的萜烯的有目的地选择的组合物 |
| CN109106699A (zh) * | 2017-06-23 | 2019-01-01 | 汉义生物科技（北京）有限公司 | 一种用于治疗癫痫的药物组合物、其制备方法及用途 |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| CN109498606A (zh) | 2017-09-15 | 2019-03-22 | 汉义生物科技（北京）有限公司 | 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用 |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| CA3085010A1 (en) * | 2017-12-08 | 2019-06-13 | Biotech Institute LLC | Propyl cannabinoid hemp plants, methods of producing and methods of using them |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| WO2020123383A1 (en) * | 2018-12-10 | 2020-06-18 | Natural Extraction Systems, LLC | Compositions with novel cannabinoid and terpene profiles |
| US20250152520A2 (en) * | 2019-03-08 | 2025-05-15 | The Regents Of The University Of California | Use of 8,9- dihydrocannabidiol compounds |
| GB201910389D0 (en) | 2019-07-19 | 2019-09-04 | Gw Pharma Ltd | Novel compounds, methods for their manufacture, and uses thereof |
| GB2588576A (en) | 2019-08-27 | 2021-05-05 | Gw Res Ltd | Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease |
| GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916846D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916977D0 (en) * | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannibidol-type cannabinoid compound |
| GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| EP4069215A4 (en) | 2019-12-06 | 2024-01-17 | Jlabs Beauty LLC | TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS OF PREPARING AND USING THE SAME |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| KR102371269B1 (ko) | 2020-03-11 | 2022-03-07 | 연세대학교 산학협력단 | VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법 |
| BR112022019616A2 (pt) * | 2020-03-31 | 2022-12-06 | Phytotherapeutix Ltd | Compostos terpenofenólicos e seu uso |
| EP4153306A4 (en) | 2020-05-22 | 2024-06-26 | Ilera Derm LLC | Compositions for treating acne and dermatological conditions |
| GB2597321A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| AU2021318553A1 (en) | 2020-07-28 | 2023-03-23 | Impello Biosciences Inc. | Methods and compositions for altering secondary metabolites in plants |
| GB202013765D0 (en) | 2020-09-02 | 2020-10-14 | Gw Res Ltd | Method of preparing cannabinoids |
| GB202014250D0 (en) * | 2020-09-10 | 2020-10-28 | Gw Res Ltd | Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| WO2022103638A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Cannabinoids in the treatment of autism spectrum disorder |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| WO2022122904A1 (en) | 2020-12-09 | 2022-06-16 | Chanelle Mccoy Cbd Limited | A delayed-release capsule of cannabidiol |
| GB2602019A (en) | 2020-12-15 | 2022-06-22 | Gw Res Ltd | Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof |
| GB2606334A (en) * | 2021-02-12 | 2022-11-09 | Gw Res Ltd | Use of cannabidivarin in the treatment of seizures associated with canine epilepsy |
| WO2024033521A1 (en) | 2022-08-12 | 2024-02-15 | GW Research Limited | Oral solid dosage forms comprising cannabinoids |
| CN115583933B (zh) * | 2022-10-31 | 2024-02-06 | 暨明医药科技（苏州）有限公司 | 一种高纯度四氢大麻素同系物的制备方法 |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6403126B1 (en) | 1999-05-26 | 2002-06-11 | Websar Innovations Inc. | Cannabinoid extraction method |
| US6949582B1 (en) | 1999-05-27 | 2005-09-27 | Wallace Walter H | Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment |
| GB0103638D0 (en) * | 2001-02-14 | 2001-03-28 | Gw Pharmaceuticals Ltd | Pharmaceutical formulations |
| DK1361864T3 (en) | 2001-02-14 | 2014-03-03 | Gw Pharma Ltd | FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids |
| GB0202385D0 (en) | 2002-02-01 | 2002-03-20 | Gw Pharma Ltd | Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions |
| ITPD20020138A1 (it) * | 2002-05-24 | 2003-11-24 | Matteo Bevilacqua | Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima. |
| DE10226494A1 (de) | 2002-06-14 | 2004-01-08 | Lts Lohmann Therapie-Systeme Ag | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
| GB2392093B (en) * | 2002-08-14 | 2006-03-08 | Gw Pharma Ltd | Pharmaceutical formulations |
| DK2311475T3 (en) | 2002-08-14 | 2016-09-19 | Gw Pharma Ltd | Extraction of pharmaceutically active cannabinoids FROM PLANT MATERIALS |
| SI1542657T1 (sl) * | 2002-08-14 | 2012-04-30 | Gw Pharma Ltd | Kanabinoidne kapljevite formulacije za sluzniäśno administracijo |
| US9168278B2 (en) | 2004-11-16 | 2015-10-27 | Gw Pharma Limited | Use for cannabinoid |
| GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| TWI366460B (en) | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
| GB2434312B (en) * | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
| WO2007142957A2 (en) | 2006-05-30 | 2007-12-13 | Air Systems | Gear drive damper |
| GB2438682A (en) * | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
| US20080188461A1 (en) | 2007-02-01 | 2008-08-07 | Regents Of The University Of Michigan | Compositions and methods for detecting, preventing and treating seizures and seizure related disorders |
| GB2448535A (en) | 2007-04-19 | 2008-10-22 | Gw Pharma Ltd | New use for cannabinoid-containing plant extracts |
| GB2449691A (en) | 2007-05-31 | 2008-12-03 | Gw Pharma Ltd | A reference plant lacking medicinal active compound expression |
| GB2450753B (en) | 2007-07-06 | 2012-07-18 | Gw Pharma Ltd | New Pharmaceutical formulation |
| GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| GB2459637B (en) | 2008-01-21 | 2012-06-06 | Gw Pharma Ltd | New use for cannabinoids |
| LT2280687T (lt) | 2008-03-26 | 2019-08-26 | Stichting Sanammad | Kramtomosios gumos kompozicijos, apimančios kanabinoidus |
| GB2478074B (en) | 2008-06-04 | 2012-12-26 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
| GB2478072B (en) | 2008-06-04 | 2012-12-26 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
| GB2471523A (en) * | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| GB2479153B (en) | 2010-03-30 | 2014-03-19 | Gw Pharma Ltd | The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy |
| US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB201111261D0 (en) | 2011-07-01 | 2011-08-17 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders |
| US9750747B2 (en) | 2011-08-26 | 2017-09-05 | Bail-Portela & Ca, S.A. | Treatments involving eslicarbazepine acetate or eslicarbazepine |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2496687A (en) | 2011-11-21 | 2013-05-22 | Gw Pharma Ltd | Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells |
| US20150181924A1 (en) | 2013-10-31 | 2015-07-02 | Michael R. Llamas | Cannabidiol liquid composition for smoking |
| US10052339B2 (en) | 2014-03-21 | 2018-08-21 | Bodybio Inc. | Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids |
| CA2950424C (en) | 2014-05-29 | 2023-03-14 | Insys Pharma, Inc. | Stable cannabinoid formulations |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
-
2011
- 2011-03-15 TW TW100108735A patent/TWI583374B/zh not_active IP Right Cessation
- 2011-03-28 AR ARP110101014 patent/AR080730A1/es unknown
- 2011-03-30 MY MYPI2012004222A patent/MY162129A/en unknown
- 2011-03-30 NZ NZ60292511A patent/NZ602925A/en unknown
- 2011-03-30 KR KR1020127028091A patent/KR101849703B1/ko active Active
- 2011-03-30 AU AU2011234225A patent/AU2011234225B2/en active Active
- 2011-03-30 EP EP20194696.9A patent/EP3763361B1/en active Active
- 2011-03-30 SG SG2012070793A patent/SG184236A1/en unknown
- 2011-03-30 WO PCT/GB2011/050649 patent/WO2011121351A1/en not_active Ceased
- 2011-03-30 SG SG10201502480XA patent/SG10201502480XA/en unknown
- 2011-03-30 CA CA2794620A patent/CA2794620C/en active Active
- 2011-03-30 BR BR112012024480A patent/BR112012024480A8/pt not_active Application Discontinuation
- 2011-03-30 CN CN201180026947.4A patent/CN103025325B/zh active Active
- 2011-03-30 MX MX2012011033A patent/MX2012011033A/es active IP Right Grant
- 2011-03-30 PH PH1/2012/501902A patent/PH12012501902A1/en unknown
- 2011-03-30 JP JP2013501945A patent/JP5918748B2/ja active Active
- 2011-03-30 EP EP11712658A patent/EP2552430A1/en not_active Withdrawn
- 2011-03-30 US US13/075,873 patent/US9125859B2/en active Active
- 2011-03-30 EA EA201290975A patent/EA036044B1/ru unknown
-
2012
- 2012-09-24 IL IL222132A patent/IL222132B/en active IP Right Grant
- 2012-10-29 ZA ZA2012/08141A patent/ZA201208141B/en unknown
-
2015
- 2015-04-14 US US14/685,753 patent/US10799467B2/en active Active
-
2016
- 2016-10-11 AU AU2016244223A patent/AU2016244223A1/en not_active Abandoned
-
2018
- 2018-08-17 AU AU2018217303A patent/AU2018217303A1/en not_active Abandoned
-
2020
- 2020-09-04 US US17/012,448 patent/US12023305B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523708A5 (https=) | ||
| Zhang et al. | Synergistic anti-inflammatory effects and mechanisms of combined phytochemicals | |
| RU2013136378A (ru) | Применение фитоканнабиноида каннабидиола(cbd) в комбинации со стандартным противоэпилептическим стедством(saed) для лечения эпилепсии | |
| FI4061344T3 (fi) | 6-hydroksikannabidioli käytettäväksi lääkkeenä | |
| KR102434817B1 (ko) | 15-hepe를 포함하는 조성물 및 그의 사용 방법 | |
| HK1247823A1 (zh) | 骨质疏松的治疗 | |
| NZ729290A (en) | Composition containing a mixture of plant extracts or a mixture of molecules contained in said plants, and use for controlling carbohydrate and/or lipid metabolism | |
| WO2013166177A3 (en) | Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation | |
| WO2009152189A8 (en) | Low dose topiramate/phentermine compostion and methods of use thereof | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2017066474A1 (en) | Compositions and methods for pain relief | |
| Adewole et al. | Exploring phytotherapeutic approach in the management of valproic acid-induced toxicity | |
| WO2008116890A3 (en) | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| Zhang et al. | From laboratory to clinic: opportunities and challenges of functional food active ingredients in cancer therapy | |
| EP2575456A4 (en) | COMPOSITIONS AND METHODS FOR TREATING PRESENTATIONS | |
| CO6241128A2 (es) | Compuestos extraidos de residuos de molienda de aceite de palma para el tratamiento del cancer composiciones de los mismos y metodos acompañantes | |
| BR112013026564A2 (pt) | uso de uma combinação | |
| JP2018529763A5 (https=) | ||
| US20090191293A1 (en) | Composition for enhancing immunity and reducing inflammation related to infections | |
| WO2011151786A3 (en) | Injectable formulation of a reverse transcriptase inhibitor for the treatment cancer | |
| MX2009013196A (es) | Profarmacos mutuos y metodos para tratar el cancer. | |
| UY33468A (es) | Agente terapeutico de liberacion sostenida para la hipertension y la disfunción renal | |
| CN101237863A (zh) | 多酚考昔联合和方法 |